CY1116062T1 - Προληπτικη και θεραπευτικη αγωγη οφθαλμικων παθησεων σχετιζομενων με συμπληρωμα - Google Patents

Προληπτικη και θεραπευτικη αγωγη οφθαλμικων παθησεων σχετιζομενων με συμπληρωμα

Info

Publication number
CY1116062T1
CY1116062T1 CY20151100205T CY151100205T CY1116062T1 CY 1116062 T1 CY1116062 T1 CY 1116062T1 CY 20151100205 T CY20151100205 T CY 20151100205T CY 151100205 T CY151100205 T CY 151100205T CY 1116062 T1 CY1116062 T1 CY 1116062T1
Authority
CY
Cyprus
Prior art keywords
eye diseases
preventive
supplemental
therapeutic
education
Prior art date
Application number
CY20151100205T
Other languages
English (en)
Inventor
Philip Hass
Yin Jianping
Kenneth Katschke Jr
Micah Steffek
Christian Wiesmann
Lookeren Campagne Menno Van
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39638868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116062(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of CY1116062T1 publication Critical patent/CY1116062T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)

Abstract

Η εφεύρεση αφορά την προληπτική και θεραπευτική αγωγή οφθαλμικών παθήσεων σχετιζόμενων με συμπλήρωμα, όπως χοριοειδούς νεοαγγείωσης (CNV) και ηλικιακής εκφύλισης ωχράς κηλίδας (AMD), με χορήγηση ανταγωνιστών παράγοντα D.
CY20151100205T 2007-05-23 2015-02-27 Προληπτικη και θεραπευτικη αγωγη οφθαλμικων παθησεων σχετιζομενων με συμπληρωμα CY1116062T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93979107P 2007-05-23 2007-05-23
EP08756130.4A EP2152755B1 (en) 2007-05-23 2008-05-22 Prevention and treatment of complement-associated eye conditions

Publications (1)

Publication Number Publication Date
CY1116062T1 true CY1116062T1 (el) 2017-02-08

Family

ID=39638868

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100205T CY1116062T1 (el) 2007-05-23 2015-02-27 Προληπτικη και θεραπευτικη αγωγη οφθαλμικων παθησεων σχετιζομενων με συμπληρωμα

Country Status (28)

Country Link
US (6) US8007791B2 (el)
EP (1) EP2152755B1 (el)
JP (4) JP5416695B2 (el)
KR (1) KR101540126B1 (el)
CN (3) CN101754980B (el)
AR (1) AR066660A1 (el)
AU (1) AU2008256835B2 (el)
BR (1) BRPI0811142A8 (el)
CA (1) CA2683498A1 (el)
CL (1) CL2008001498A1 (el)
CY (1) CY1116062T1 (el)
DK (1) DK2152755T3 (el)
ES (1) ES2533242T3 (el)
HK (2) HK1139161A1 (el)
HR (1) HRP20150281T1 (el)
IL (2) IL201476A (el)
MX (1) MX2009012422A (el)
PE (1) PE20090294A1 (el)
PH (1) PH12013500992A1 (el)
PL (1) PL2152755T3 (el)
PT (1) PT2152755E (el)
RS (1) RS53901B1 (el)
RU (2) RU2522976C2 (el)
SG (1) SG10201401404RA (el)
SI (1) SI2152755T1 (el)
TW (2) TWI419704B (el)
WO (1) WO2008147883A1 (el)
ZA (1) ZA200907028B (el)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60136272D1 (de) * 2000-04-29 2008-12-04 Univ Iowa Res Found Diagnostika und therapeutika für makula degeneration erkrankungen
UA99591C2 (ru) * 2005-11-04 2012-09-10 Дженентек, Инк. Применение ингибиторов пути комплемента для лечения глазных болезней
PL2097455T3 (pl) 2006-11-02 2015-04-30 Genentech Inc Humanizowane przeciwciała przeciw czynnikowi D
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
MX2011002367A (es) * 2008-09-02 2011-04-04 Novartis Ag Inhibidores de cinasa biciclicos.
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CN104887389B (zh) 2009-01-29 2017-06-23 弗赛特影像4股份有限公司 后段给药
EP2427479B1 (en) * 2009-05-07 2018-11-21 The Regents of The University of California Antibodies and methods of use thereof
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
HUE057267T2 (hu) * 2010-08-05 2022-05-28 Forsight Vision4 Inc Berendezés szem kezelésére
MX348025B (es) 2010-11-01 2017-05-24 Genentech Inc * Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica.
KR20140027090A (ko) 2011-01-04 2014-03-06 노파르티스 아게 연령-관련 황반 변성 (amd)의 치료에 유용한 인돌 화합물 또는 그의 유사체
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
US9815819B2 (en) 2012-06-28 2017-11-14 Novartis Ag Complement pathway modulators and uses thereof
WO2014002054A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US9487483B2 (en) 2012-06-28 2016-11-08 Novartis Ag Complement pathway modulators and uses thereof
EP2867224B1 (en) 2012-06-28 2017-07-26 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
WO2014002052A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US9550755B2 (en) 2012-07-12 2017-01-24 Novartis Ag Complement pathway modulators and uses thereof
SG11201500489YA (en) 2012-07-25 2015-02-27 Kolltan Pharmaceuticals Inc Anti-kit antibodies and uses thereof
WO2014120555A1 (en) 2013-01-31 2014-08-07 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of use thereof
EP4302736A3 (en) 2013-03-28 2024-04-03 ForSight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
AU2014332021B2 (en) * 2013-10-07 2020-05-07 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
CN105764533A (zh) * 2013-10-25 2016-07-13 儿童医疗中心有限公司 治疗或预防视网膜血管疾病的方法
CA2944712A1 (en) * 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
CA2998500A1 (en) * 2015-09-23 2017-03-30 Sangamo Therapeutics, Inc. Htt repressors and uses thereof
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
US10421821B2 (en) 2015-10-30 2019-09-24 Genentech, Inc. Anti-HtrA1 antibodies and methods of use thereof
EP3368682B1 (en) 2015-10-30 2019-12-11 H. Hoffnabb-La Roche Ag Methods of measuring factor d activity and potency of factor d inhibitors
JP2018534930A (ja) * 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
MX2018007392A (es) * 2015-12-23 2018-08-15 Greenovation Biotech Gmbh Polipeptidos para inhibir la activacion del complemento.
AU2017210042B2 (en) 2016-01-20 2021-01-21 396419 B.C. Ltd. Compositions and methods for inhibiting Factor D
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
EP3580241A4 (en) * 2017-02-10 2021-01-06 The Trustees Of The University Of Pennsylvania ANTIFACTOR D ANTIBODIES AND USES THEREOF
CN109632924B (zh) * 2018-12-17 2022-02-08 上海市第一人民医院 人黄斑新生血管性疾病的血浆脂质标记物及其应用
WO2021009777A2 (en) * 2019-07-18 2021-01-21 Pandorum Technologies Private Limited Methods of stem cell culture for obtaining products, and implementations thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620915B2 (en) * 1993-12-23 2003-09-16 Icos Corporation Monoclonal antibodies specific for integrin α-d subunit
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
WO1999027098A2 (en) 1997-11-21 1999-06-03 Genentech, Inc. A-33 related antigens and their pharmacological uses
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
AU2577799A (en) 1998-02-09 1999-08-23 Human Genome Sciences, Inc. 45 human secreted proteins
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
ES2488819T3 (es) * 1998-02-20 2014-08-29 Genentech, Inc. Inhibidores de la activación del complemento
PT1490386E (pt) 1998-03-10 2008-11-24 Genentech Inc Novos polipéptidos e ácidos nucleicos que os codificam
AU5587799A (en) 1998-08-27 2000-03-21 Incyte Pharmaceuticals, Inc. Protein transport-associated molecules
EP1141285A2 (en) 1998-12-16 2001-10-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP4632543B2 (ja) * 1998-12-21 2011-02-16 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 切断ｖｅｇｆ−ｄの抗体及びその利用法
JP3993746B2 (ja) 1998-12-22 2007-10-17 ジェネンテック・インコーポレーテッド 腫瘍性細胞成長阻害のための組成物及び方法
CA2362427A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CZ303128B6 (cs) 1999-03-11 2012-04-18 Laboratoires Serono Sa Adhezní molekula 1 regulovaná konfluencí CRAM-1, její kódující nukleová kyselina, protilátky a použití
US6642353B1 (en) 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
AU2883900A (en) 1999-07-07 2001-01-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
UA72943C2 (uk) 1999-11-02 2005-05-16 Ульяновскій Государствєнний Тєхніческій Унівєрсітєт Спосіб очищення рідини від феромагнітних частинок (варіанти) і пристрій для його здійснення (варіанти)
JP2003514541A (ja) 1999-11-19 2003-04-22 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １８個のヒト分泌タンパク質
EP1690872A3 (en) 1999-12-01 2006-08-23 Genentech, Inc. Composition and methods for the diagnosis of tumours
CA2412211A1 (en) 2000-06-23 2002-01-03 Genetech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20040152105A1 (en) 2002-09-06 2004-08-05 Cytos Biotechnology Ag. Immune modulatory compounds and methods
RU2232991C1 (ru) * 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
UA99591C2 (ru) 2005-11-04 2012-09-10 Дженентек, Инк. Применение ингибиторов пути комплемента для лечения глазных болезней
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
PL2097455T3 (pl) * 2006-11-02 2015-04-30 Genentech Inc Humanizowane przeciwciała przeciw czynnikowi D
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
JP4349447B2 (ja) 2007-07-19 2009-10-21 トヨタ自動車株式会社 インバータ制御装置および車両

Also Published As

Publication number Publication date
TWI419704B (zh) 2013-12-21
PE20090294A1 (es) 2009-03-27
US20180079826A1 (en) 2018-03-22
US20090181017A1 (en) 2009-07-16
AU2008256835A1 (en) 2008-12-04
PH12013500992B1 (en) 2016-01-25
CN101754980B (zh) 2014-10-29
EP2152755B1 (en) 2014-12-31
WO2008147883A1 (en) 2008-12-04
DK2152755T3 (en) 2015-03-02
SG10201401404RA (en) 2014-08-28
TW201417829A (zh) 2014-05-16
RU2522976C2 (ru) 2014-07-20
TW200904471A (en) 2009-02-01
JP5416695B2 (ja) 2014-02-12
PH12013500992A1 (en) 2016-01-25
PL2152755T3 (pl) 2015-06-30
HK1139161A1 (en) 2010-09-10
MX2009012422A (es) 2009-12-04
US8497094B2 (en) 2013-07-30
CL2008001498A1 (es) 2009-06-12
CN107096029A (zh) 2017-08-29
CN107096029B (zh) 2021-02-26
JP2014087346A (ja) 2014-05-15
AU2008256835B2 (en) 2013-08-01
BRPI0811142A2 (pt) 2014-12-23
PT2152755E (pt) 2015-04-01
JP2010528047A (ja) 2010-08-19
HRP20150281T1 (hr) 2015-04-10
CA2683498A1 (en) 2008-12-04
HK1207327A1 (en) 2016-01-29
US20130052685A1 (en) 2013-02-28
RU2009147744A (ru) 2011-06-27
US20130302333A1 (en) 2013-11-14
IL248552A0 (en) 2016-12-29
KR20100033973A (ko) 2010-03-31
CN104367999A (zh) 2015-02-25
RS53901B1 (en) 2015-08-31
US20110282034A1 (en) 2011-11-17
CN101754980A (zh) 2010-06-23
IL201476A (en) 2016-11-30
BRPI0811142A8 (pt) 2018-12-18
KR101540126B1 (ko) 2015-07-28
SI2152755T1 (sl) 2015-05-29
RU2014113046A (ru) 2015-10-10
US8268310B2 (en) 2012-09-18
WO2008147883A8 (en) 2013-05-23
AR066660A1 (es) 2009-09-02
EP2152755A1 (en) 2010-02-17
ES2533242T3 (es) 2015-04-08
US8007791B2 (en) 2011-08-30
IL201476A0 (en) 2010-05-31
ZA200907028B (en) 2010-12-29
US20160272726A1 (en) 2016-09-22
JP2016145205A (ja) 2016-08-12
JP2017197577A (ja) 2017-11-02

Similar Documents

Publication Publication Date Title
CY1116062T1 (el) Προληπτικη και θεραπευτικη αγωγη οφθαλμικων παθησεων σχετιζομενων με συμπληρωμα
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
MX2015012435A (es) Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmicos.
CY1120213T1 (el) Antαγωνιστες φθοριωμενης ιντεγκρινης
EA201001639A1 (ru) Композиции и способы их получения и применения
TN2013000275A1 (en) Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
MX2019001021A (es) Formulaciones de liposomas.
EA201270018A1 (ru) Опсинсвязывающие лиганды, композиции и способы использования
EA201290498A1 (ru) Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
MX343688B (es) Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
MX2010003949A (es) N-fenil-bipirrolidina carboxamidas sustituidas y uso terapeutico de las mismas.
TN2011000647A1 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases such as e.g. malaria
BRPI0820343A2 (pt) Anticorpos de antifator b e seus usos
UA109414C2 (uk) Арильовані камфени та фармацевтична композиція на їх основі
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
MX2016009600A (es) Agentes para utilizarse en el tratamiento de la inflamacion de retina.
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
CL2018001370A1 (es) Derivados novedosos de diamino piridina
TW200744627A (en) Methods for the treatment of macular degeneration and related eye conditions
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
TW200744670A (en) Methods for the treatment of macular degeneration and related eye conditions
GB201206984D0 (en) New therapeutic use